2025 Q3 -tulosraportti
19 päivää sittenTarjoustasot
Spotlight Stock Market DK
Määrä
Osto
5 000
Myynti
Määrä
1 171
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 350 | NON | NON | ||
| 10 | NON | NON | ||
| 100 | NON | NON | ||
| 99 | NON | NON | ||
| 2 000 | NON | SSWM |
Ylin
10,3VWAP
Alin
9,42VaihtoMäärä
0,1 5 206
VWAP
Ylin
10,3Alin
9,42VaihtoMäärä
0,1 5 206
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 6 961 | 4 377 | +2 584 | 2 510 |
| SSW Market Making GmbH | 1 867 | 2 000 | −133 | 0 |
| Danske Bank A/S | 0 | 2 451 | −2 451 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 0 | 2 451 | −2 451 | 0 |
| SSW Market Making GmbH | 1 867 | 2 000 | −133 | 0 |
| Nordnet Bank AB | 6 961 | 4 377 | +2 584 | 2 510 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·35 min sittenIt looks like we'll have a cautious day without much trading volume. Under 4000 units so far..·10 min sittenAs I have understood it, the patient must first have uTRACE to see if the cancer is uPAR active. I think that there there after a a pause to ensure that uTRACE is out of the body again so uPAR is ready to receive uTREAT. I have not been able to find information about how long this pause is. According to the protocol, it was only on 11 dec that Recruitment finally opened. So I do not think that FPD has been there yet. They could perhaps have communicated more clearly that Recruitment was only on 11 dec.
·12 t sitten · MuokattuThis is how much the shares have been diluted since the start in 2020 Date Total # shares Dilution % 22-10-2020 17.126.340 0,00 % 07-10-2021 19.893.891(TO1) 13,91 % 10-12-2024 21.148.880(TO2) 2,21 % 21-05-2025 44.886.242 52,88 % 02-06-2025 45.864.010 2,13 % 18-06-2025 45.867.511(TO3) 0,01 % 12-12-2025 47.922.841 4,29 % We hope that it holds until The Main Event 🚀 (it's a poor editor..! 👀)·20 min sitten · MuokattuThere is actually a potential dilution ahead if Fenja exercises its conversion right in connection with the loan of 25 mill (at a price of 9,975) Fenja, conversion (max) 50.429.107 4,97% Let's hope that Fenja finds it attractive to exercise the conversion right 😉 That gives a total accumulated dilution of 66,20 % since start.
·16 t sitten · MuokattuShould people have forgotten this statement from Curasight itself, November 27; Spend 35 seconds listening: https://www.youtube.com/live/wUo3kZQywaA?si=odhdQYzW7auY_Z2a&t=1230 "Our test site is ready. There is nothing else but for the first patient, who is suitable and says yes to participate, to arrive. Therefore, we expect it to happen here now, within the next weeks and in any case within q4. And where we will then already be able to see the first data."·14 t sittenIt is quite interesting, as they first received the final approval from EMA for the start of the study on Dec 11. It also appears from this that there will only be Danish patients, and that 6 patients will be enrolled in this phase and that Rigshospitalet is responsible for the study. https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 By opening the Clinical Trial document (link can be found at the top right in the above link) one can find the following interesting information (and many more): - Start of Trial: 2025-11-25 - Start of recruitment: 2025-12-11 - Estimated end of trial date in EU/EEA: 2026-05-15 - Planned number of subjects: 6 - Site: Rigshospitalet As previously mentioned, they have been slightly delayed with the approval for the start of the study, but that is naturally okay (just a bit of impatience) It will be extremely interesting whether they can deliver on their milestones in 2026. The entire planning looks good, and phase 2 of prostate seems to be well 'on track'. There will naturally be uncertainties and probably also delays and setbacks, but as long as the technology platform holds, an acquisition awaits!
·21 t sittenHow much further down do we expect it to go in the next couple of weeks/months? And how far along are they with finding a patient for dosing?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
19 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·35 min sittenIt looks like we'll have a cautious day without much trading volume. Under 4000 units so far..·10 min sittenAs I have understood it, the patient must first have uTRACE to see if the cancer is uPAR active. I think that there there after a a pause to ensure that uTRACE is out of the body again so uPAR is ready to receive uTREAT. I have not been able to find information about how long this pause is. According to the protocol, it was only on 11 dec that Recruitment finally opened. So I do not think that FPD has been there yet. They could perhaps have communicated more clearly that Recruitment was only on 11 dec.
- ·12 t sitten · MuokattuThis is how much the shares have been diluted since the start in 2020 Date Total # shares Dilution % 22-10-2020 17.126.340 0,00 % 07-10-2021 19.893.891(TO1) 13,91 % 10-12-2024 21.148.880(TO2) 2,21 % 21-05-2025 44.886.242 52,88 % 02-06-2025 45.864.010 2,13 % 18-06-2025 45.867.511(TO3) 0,01 % 12-12-2025 47.922.841 4,29 % We hope that it holds until The Main Event 🚀 (it's a poor editor..! 👀)·20 min sitten · MuokattuThere is actually a potential dilution ahead if Fenja exercises its conversion right in connection with the loan of 25 mill (at a price of 9,975) Fenja, conversion (max) 50.429.107 4,97% Let's hope that Fenja finds it attractive to exercise the conversion right 😉 That gives a total accumulated dilution of 66,20 % since start.
- ·16 t sitten · MuokattuShould people have forgotten this statement from Curasight itself, November 27; Spend 35 seconds listening: https://www.youtube.com/live/wUo3kZQywaA?si=odhdQYzW7auY_Z2a&t=1230 "Our test site is ready. There is nothing else but for the first patient, who is suitable and says yes to participate, to arrive. Therefore, we expect it to happen here now, within the next weeks and in any case within q4. And where we will then already be able to see the first data."·14 t sittenIt is quite interesting, as they first received the final approval from EMA for the start of the study on Dec 11. It also appears from this that there will only be Danish patients, and that 6 patients will be enrolled in this phase and that Rigshospitalet is responsible for the study. https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 By opening the Clinical Trial document (link can be found at the top right in the above link) one can find the following interesting information (and many more): - Start of Trial: 2025-11-25 - Start of recruitment: 2025-12-11 - Estimated end of trial date in EU/EEA: 2026-05-15 - Planned number of subjects: 6 - Site: Rigshospitalet As previously mentioned, they have been slightly delayed with the approval for the start of the study, but that is naturally okay (just a bit of impatience) It will be extremely interesting whether they can deliver on their milestones in 2026. The entire planning looks good, and phase 2 of prostate seems to be well 'on track'. There will naturally be uncertainties and probably also delays and setbacks, but as long as the technology platform holds, an acquisition awaits!
- ·21 t sittenHow much further down do we expect it to go in the next couple of weeks/months? And how far along are they with finding a patient for dosing?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
5 000
Myynti
Määrä
1 171
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 350 | NON | NON | ||
| 10 | NON | NON | ||
| 100 | NON | NON | ||
| 99 | NON | NON | ||
| 2 000 | NON | SSWM |
Ylin
10,3VWAP
Alin
9,42VaihtoMäärä
0,1 5 206
VWAP
Ylin
10,3Alin
9,42VaihtoMäärä
0,1 5 206
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 6 961 | 4 377 | +2 584 | 2 510 |
| SSW Market Making GmbH | 1 867 | 2 000 | −133 | 0 |
| Danske Bank A/S | 0 | 2 451 | −2 451 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 0 | 2 451 | −2 451 | 0 |
| SSW Market Making GmbH | 1 867 | 2 000 | −133 | 0 |
| Nordnet Bank AB | 6 961 | 4 377 | +2 584 | 2 510 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
2025 Q3 -tulosraportti
19 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 19.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 27.11. | |
| 2025 Q2 -tulosraportti | 28.8. | |
| 2025 Q1 -tulosraportti | 25.4. | |
| 2024 Q4 -tulosraportti | 27.2. | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Datan lähde: Quartr, FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·35 min sittenIt looks like we'll have a cautious day without much trading volume. Under 4000 units so far..·10 min sittenAs I have understood it, the patient must first have uTRACE to see if the cancer is uPAR active. I think that there there after a a pause to ensure that uTRACE is out of the body again so uPAR is ready to receive uTREAT. I have not been able to find information about how long this pause is. According to the protocol, it was only on 11 dec that Recruitment finally opened. So I do not think that FPD has been there yet. They could perhaps have communicated more clearly that Recruitment was only on 11 dec.
- ·12 t sitten · MuokattuThis is how much the shares have been diluted since the start in 2020 Date Total # shares Dilution % 22-10-2020 17.126.340 0,00 % 07-10-2021 19.893.891(TO1) 13,91 % 10-12-2024 21.148.880(TO2) 2,21 % 21-05-2025 44.886.242 52,88 % 02-06-2025 45.864.010 2,13 % 18-06-2025 45.867.511(TO3) 0,01 % 12-12-2025 47.922.841 4,29 % We hope that it holds until The Main Event 🚀 (it's a poor editor..! 👀)·20 min sitten · MuokattuThere is actually a potential dilution ahead if Fenja exercises its conversion right in connection with the loan of 25 mill (at a price of 9,975) Fenja, conversion (max) 50.429.107 4,97% Let's hope that Fenja finds it attractive to exercise the conversion right 😉 That gives a total accumulated dilution of 66,20 % since start.
- ·16 t sitten · MuokattuShould people have forgotten this statement from Curasight itself, November 27; Spend 35 seconds listening: https://www.youtube.com/live/wUo3kZQywaA?si=odhdQYzW7auY_Z2a&t=1230 "Our test site is ready. There is nothing else but for the first patient, who is suitable and says yes to participate, to arrive. Therefore, we expect it to happen here now, within the next weeks and in any case within q4. And where we will then already be able to see the first data."·14 t sittenIt is quite interesting, as they first received the final approval from EMA for the start of the study on Dec 11. It also appears from this that there will only be Danish patients, and that 6 patients will be enrolled in this phase and that Rigshospitalet is responsible for the study. https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2024-520105-39-00 By opening the Clinical Trial document (link can be found at the top right in the above link) one can find the following interesting information (and many more): - Start of Trial: 2025-11-25 - Start of recruitment: 2025-12-11 - Estimated end of trial date in EU/EEA: 2026-05-15 - Planned number of subjects: 6 - Site: Rigshospitalet As previously mentioned, they have been slightly delayed with the approval for the start of the study, but that is naturally okay (just a bit of impatience) It will be extremely interesting whether they can deliver on their milestones in 2026. The entire planning looks good, and phase 2 of prostate seems to be well 'on track'. There will naturally be uncertainties and probably also delays and setbacks, but as long as the technology platform holds, an acquisition awaits!
- ·21 t sittenHow much further down do we expect it to go in the next couple of weeks/months? And how far along are they with finding a patient for dosing?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
5 000
Myynti
Määrä
1 171
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 350 | NON | NON | ||
| 10 | NON | NON | ||
| 100 | NON | NON | ||
| 99 | NON | NON | ||
| 2 000 | NON | SSWM |
Ylin
10,3VWAP
Alin
9,42VaihtoMäärä
0,1 5 206
VWAP
Ylin
10,3Alin
9,42VaihtoMäärä
0,1 5 206
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordnet Bank AB | 6 961 | 4 377 | +2 584 | 2 510 |
| SSW Market Making GmbH | 1 867 | 2 000 | −133 | 0 |
| Danske Bank A/S | 0 | 2 451 | −2 451 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Danske Bank A/S | 0 | 2 451 | −2 451 | 0 |
| SSW Market Making GmbH | 1 867 | 2 000 | −133 | 0 |
| Nordnet Bank AB | 6 961 | 4 377 | +2 584 | 2 510 |